Brief: Stoke Therapeutics Q1 Basic Loss Per Share $0.53
04/05/2023 12:37
May 4 (Reuters) - Stoke Therapeutics Q1 revenue USD 5.152 million. * Q1 operating expenses USD 29.842 million * Q1 operating income USD -24.69 million * Q1 basic EPS USD -0.53 * Q1 net income USD -22.545 million
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics